Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: li3511 who wrote (63280)	11/5/2025 1:45:28 AM
From: ghettogoulash	2 Recommendations Recommended By jhcimmu Olecranon Read Replies (1) of 63311

Indeed, this will be a tough sell to Prasad & Co. Then again, it's gonna take some big balls to withdraw these therapies from patients. I think we see $10 again. I sold 3/4 of my position at $19, bought some back in the $15s, and will be averaging down from there if I am right. The semiconductor/AI sector, which seems to be about 90% of the market these days, is showing signs of rolling over on these absurd valuations, which unfortunately will take everything else with it. Reinstatement of Elevidys is taking longer than I expected; guidance for flat revenue next quarter is a surprise. As for the PMOs, I was not at all surprised by the trial results. I have been dreading that readout. However, it would seem that Elevidys is expected to supplant those therapies anyway except in certain cases, most notably, non-ambulatory patients and others ineligible for gene therapy. As an investor, I am in no hurry to reinstate non-ambulatory to Elevidys' label. Too much risk. Unless of course those patients are demanding the drug.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next